Press Releases April 2, 2026 05:38 PM

DeFi Development Corp. to Host X Spaces Event: “DFDV March 2026 Recap & AMA + FY 2025 Earnings Breakdown”

DeFi Development Corp. to Host Live X Spaces Event Covering March 2026 Recap and FY 2025 Earnings Breakdown

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
DFDV

DeFi Development Corp. (Nasdaq: DFDV), a U.S.-based company centered on Solana treasury strategies and DeFi participation, will hold a live X Spaces event on April 6, 2026. The event aims to provide shareholders and the community with a recap of recent progress and discuss financial updates, without disclosing material nonpublic information.

DeFi Development Corp. to Host X Spaces Event: “DFDV March 2026 Recap & AMA + FY 2025 Earnings Breakdown”
DFDV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • DeFi Development Corp. focuses its treasury reserves primarily on Solana (SOL), providing investors exposure to this cryptocurrency.
  • The company operates validator infrastructure, earning staking rewards and staking fees, positioning itself deeply within Solana's ecosystem.
  • Beyond crypto, the company also offers AI-powered online platforms delivering SaaS solutions to commercial real estate professionals, connecting complex stakeholder ecosystems.

BOCA RATON, FL, April 02, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (“DFDV” or the “Company”), the first U.S. public company with a treasury strategy built around accumulating and compounding Solana (SOL), today announced it will host a live X Spaces event on Monday, April 6, 2026, at 1:00 PM ET.

The event will provide shareholders, analysts, and the broader community with a comprehensive recap of DFDV’s progress during March 2026 and discuss the Company’s latest 2026 investor letter.

Participants can join the live event by visiting DeFi Development Corp.’s official X account at the scheduled time. A recording of the conversation will be made available shortly after the event concludes.

Join the conversation: https://x.com/i/spaces/1NxaraMBXgRKj?s=20.

The Company does not intend to disclose any material nonpublic information during the event.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Investor Contact:
[email protected]

Media Contact:
[email protected]


Risks

  • The company's heavy reliance on Solana (SOL) exposes it to cryptocurrency market volatility, impacting treasury asset value.
  • Participation in decentralized finance and blockchain sectors entails regulatory uncertainties that could affect operations.
  • Competition and market adoption challenges for its AI-powered SaaS platform in commercial real estate could affect growth and revenue.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026